Sanofi (NASDAQ:SNY) Stock Holdings Lifted by Zions Bancorporation N.A.

Zions Bancorporation N.A. raised its position in Sanofi (NASDAQ:SNY - Free Report) by 7.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 165,350 shares of the company's stock after purchasing an additional 10,990 shares during the quarter. Zions Bancorporation N.A.'s holdings in Sanofi were worth $7,975,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SNY. Synergy Asset Management LLC acquired a new position in Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. lifted its position in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi in the fourth quarter valued at $31,000. Sunbelt Securities Inc. grew its holdings in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new stake in Sanofi during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of NASDAQ SNY traded up $0.91 during midday trading on Friday, reaching $55.82. 2,059,619 shares of the company traded hands, compared to its average volume of 2,268,963. The company has a market cap of $141.66 billion, a price-to-earnings ratio of 22.42, a PEG ratio of 1.01 and a beta of 0.58. The stock has a 50-day moving average price of $55.13 and a 200 day moving average price of $52.79. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SNY has been the subject of a number of recent analyst reports. StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.